Skip to main content
Erschienen in: Cardiovascular Drugs and Therapy 1/2015

01.02.2015 | REVIEW ARTICLE

Oxidative Stress and Early Atherosclerosis: Novel Antioxidant Treatment

verfasst von: Dimitris Tousoulis, Theodora Psaltopoulou, Emmanuel Androulakis, Nikolaos Papageorgiou, Spyridon Papaioannou, Evangelos Oikonomou, Andreas Synetos, Christodoulos Stefanadis

Erschienen in: Cardiovascular Drugs and Therapy | Ausgabe 1/2015

Einloggen, um Zugang zu erhalten

Abstract

Atherosclerotic lesions initiate in regions characterized by low shear stress and reduced activity of endothelial atheroprotective molecules such as nitric oxide, which is the key molecule managing vascular homeostasis. The generation of reactive oxygen species from the vascular endothelium is strongly related to various enzymes, such as xanthine oxidase, endothelial nitric oxide synthase and nicotinamide-adenine dinucleotide phosphate oxidase. Several pharmaceutical agents, including angiotensin converting enzyme inhibitors, angiotensin receptors blockers and statins, along with a variety of other agents, have demonstrated additional antioxidant properties beyond their principal role. Reports regarding the antioxidant role of vitamins present controversial results, especially those based on large scale studies. In addition, there is growing interest on the role of dietary flavonoids and their potential to improve endothelial function by modifying the oxidative stress status. However, the vascular-protective role of flavonoids and especially their antioxidant properties are still under investigation. Indeed, further research is required to establish the impact of the proposed new therapeutic strategies in atherosclerosis.
Literatur
1.
Zurück zum Zitat Okazaki S, Sakaguchi M, Miwa K, et al. Association of interleukin-6 with the progression of carotid atherosclerosis: a 9-year follow-up study. Stroke; J Cereb Circ. 2014;45:2924–9. Okazaki S, Sakaguchi M, Miwa K, et al. Association of interleukin-6 with the progression of carotid atherosclerosis: a 9-year follow-up study. Stroke; J Cereb Circ. 2014;45:2924–9.
2.
Zurück zum Zitat Tousoulis D, Kampoli AM, Papageorgiou N, et al. Pathophysiology of atherosclerosis: the role of inflammation. Curr Pharm Des. 2011;17:4089–110.PubMed Tousoulis D, Kampoli AM, Papageorgiou N, et al. Pathophysiology of atherosclerosis: the role of inflammation. Curr Pharm Des. 2011;17:4089–110.PubMed
3.
Zurück zum Zitat Gutstein DE, Fuster V. Pathophysiology and clinical significance of atherosclerotic plaque rupture. Cardiovasc Res. 1999;41:323–33.PubMed Gutstein DE, Fuster V. Pathophysiology and clinical significance of atherosclerotic plaque rupture. Cardiovasc Res. 1999;41:323–33.PubMed
4.
Zurück zum Zitat Sandoo A, van Zanten JJ, Metsios GS, Carroll D, Kitas GD. The endothelium and its role in regulating vascular tone. Open Cardiovasc Med J. 2010;4:302–12.PubMedCentralPubMed Sandoo A, van Zanten JJ, Metsios GS, Carroll D, Kitas GD. The endothelium and its role in regulating vascular tone. Open Cardiovasc Med J. 2010;4:302–12.PubMedCentralPubMed
5.
Zurück zum Zitat Guzik TJ, Sadowski J, Kapelak B, et al. Systemic regulation of vascular NAD(P)H oxidase activity and nox isoform expression in human arteries and veins. Arterioscler Thromb Vasc Biol. 2004;24:1614–20.PubMed Guzik TJ, Sadowski J, Kapelak B, et al. Systemic regulation of vascular NAD(P)H oxidase activity and nox isoform expression in human arteries and veins. Arterioscler Thromb Vasc Biol. 2004;24:1614–20.PubMed
6.
Zurück zum Zitat Deanfield JE, Halcox JP, Rabelink TJ. Endothelial function and dysfunction: testing and clinical relevance. Circulation. 2007;115:1285–95.PubMed Deanfield JE, Halcox JP, Rabelink TJ. Endothelial function and dysfunction: testing and clinical relevance. Circulation. 2007;115:1285–95.PubMed
7.
Zurück zum Zitat Wind S, Beuerlein K, Eucker T, et al. Comparative pharmacology of chemically distinct NADPH oxidase inhibitors. Br J Pharmacol. 2010;161:885–98.PubMedCentralPubMed Wind S, Beuerlein K, Eucker T, et al. Comparative pharmacology of chemically distinct NADPH oxidase inhibitors. Br J Pharmacol. 2010;161:885–98.PubMedCentralPubMed
8.
Zurück zum Zitat Martin A, Frei B. Both intracellular and extracellular vitamin C inhibit atherogenic modification of LDL by human vascular endothelial cells. Arterioscler Thromb Vasc Biol. 1997;17:1583–90.PubMed Martin A, Frei B. Both intracellular and extracellular vitamin C inhibit atherogenic modification of LDL by human vascular endothelial cells. Arterioscler Thromb Vasc Biol. 1997;17:1583–90.PubMed
9.
Zurück zum Zitat Pusparini, Dharma R, Suyatna FD, Mansyur M, Hidajat A. Effect of soy isoflavone supplementation on vascular endothelial function and oxidative stress in postmenopausal women: a community randomized controlled trial. Asia Pac J Clin Nutr. 2013;22:357–64.PubMed Pusparini, Dharma R, Suyatna FD, Mansyur M, Hidajat A. Effect of soy isoflavone supplementation on vascular endothelial function and oxidative stress in postmenopausal women: a community randomized controlled trial. Asia Pac J Clin Nutr. 2013;22:357–64.PubMed
10.
Zurück zum Zitat Siasos G, Tousoulis D, Kokkou E, et al. Favorable effects of concord grape juice on endothelial function and arterial stiffness in healthy smokers. Am J Hypertens. 2014;27:38–45.PubMed Siasos G, Tousoulis D, Kokkou E, et al. Favorable effects of concord grape juice on endothelial function and arterial stiffness in healthy smokers. Am J Hypertens. 2014;27:38–45.PubMed
11.
Zurück zum Zitat Binder RL, Gallagher PM, Johnson GR, et al. Evidence that initiated keratinocytes clonally expand into multiple existing hair follicles during papilloma histogenesis in SENCAR mouse skin. Mol Carcinog. 1997;20:151–8.PubMed Binder RL, Gallagher PM, Johnson GR, et al. Evidence that initiated keratinocytes clonally expand into multiple existing hair follicles during papilloma histogenesis in SENCAR mouse skin. Mol Carcinog. 1997;20:151–8.PubMed
12.
Zurück zum Zitat Galley HF, Webster NR. Physiology of the endothelium. Br J Anaesth. 2004;93:105–13.PubMed Galley HF, Webster NR. Physiology of the endothelium. Br J Anaesth. 2004;93:105–13.PubMed
13.
Zurück zum Zitat Ignarro LJ. Biosynthesis and metabolism of endothelium-derived nitric oxide. Annu Rev Pharmacol Toxicol. 1990;30:535–60.PubMed Ignarro LJ. Biosynthesis and metabolism of endothelium-derived nitric oxide. Annu Rev Pharmacol Toxicol. 1990;30:535–60.PubMed
14.
Zurück zum Zitat Esper RJ, Nordaby RA, Vilarino JO, Paragano A, Cacharron JL, Machado RA. Endothelial dysfunction: a comprehensive appraisal. Cardiovasc Diabetol. 2006;5:4.PubMedCentralPubMed Esper RJ, Nordaby RA, Vilarino JO, Paragano A, Cacharron JL, Machado RA. Endothelial dysfunction: a comprehensive appraisal. Cardiovasc Diabetol. 2006;5:4.PubMedCentralPubMed
15.
Zurück zum Zitat Wennmalm A. Endothelial nitric oxide and cardiovascular disease. J Intern Med. 1994;235:317–27.PubMed Wennmalm A. Endothelial nitric oxide and cardiovascular disease. J Intern Med. 1994;235:317–27.PubMed
16.
Zurück zum Zitat Breton-Romero R, Acin-Perez R, Rodriguez-Pascual F, et al. Laminar shear stress regulates mitochondrial dynamics, bioenergetics responses and PRX3 activation in endothelial cells. Biochim Biophys Acta. 1843;2014:2403–13. Breton-Romero R, Acin-Perez R, Rodriguez-Pascual F, et al. Laminar shear stress regulates mitochondrial dynamics, bioenergetics responses and PRX3 activation in endothelial cells. Biochim Biophys Acta. 1843;2014:2403–13.
17.
Zurück zum Zitat Antoniades C, Bakogiannis C, Leeson P, et al. Rapid, direct effects of statin treatment on arterial redox state and nitric oxide bioavailability in human atherosclerosis via tetrahydrobiopterin-mediated endothelial nitric oxide synthase coupling. Circulation. 2011;124:335–45.PubMed Antoniades C, Bakogiannis C, Leeson P, et al. Rapid, direct effects of statin treatment on arterial redox state and nitric oxide bioavailability in human atherosclerosis via tetrahydrobiopterin-mediated endothelial nitric oxide synthase coupling. Circulation. 2011;124:335–45.PubMed
18.
Zurück zum Zitat Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med. 2005;352:1685–95.PubMed Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med. 2005;352:1685–95.PubMed
19.
Zurück zum Zitat Pirs M, Jug B, Erzen B, et al. Relationship between markers of endothelial dysfunction and inflammation and subclinical atherosclerosis in HIV-infected male patients below 55 years of age. Acta dermatovenerologica Alpina, Pannonica, et Adriatica. 2014;23:49–52.PubMed Pirs M, Jug B, Erzen B, et al. Relationship between markers of endothelial dysfunction and inflammation and subclinical atherosclerosis in HIV-infected male patients below 55 years of age. Acta dermatovenerologica Alpina, Pannonica, et Adriatica. 2014;23:49–52.PubMed
20.
Zurück zum Zitat Choi BJ, Matsuo Y, Aoki T et al. Coronary Endothelial Dysfunction Is Associated With Inflammation and Vasa Vasorum Proliferation in Patients with Early Atherosclerosis. Arterioscler Thromb Vasc Biol 2014. Choi BJ, Matsuo Y, Aoki T et al. Coronary Endothelial Dysfunction Is Associated With Inflammation and Vasa Vasorum Proliferation in Patients with Early Atherosclerosis. Arterioscler Thromb Vasc Biol 2014.
21.
Zurück zum Zitat Martin BJ, Anderson TJ. Risk prediction in cardiovascular disease: the prognostic significance of endothelial dysfunction. Can J Cardiol. 2009;25(Suppl A):15A–20A.PubMedCentralPubMed Martin BJ, Anderson TJ. Risk prediction in cardiovascular disease: the prognostic significance of endothelial dysfunction. Can J Cardiol. 2009;25(Suppl A):15A–20A.PubMedCentralPubMed
22.
Zurück zum Zitat Halcox JP, Schenke WH, Zalos G, et al. Prognostic value of coronary vascular endothelial dysfunction. Circulation. 2002;106:653–8.PubMed Halcox JP, Schenke WH, Zalos G, et al. Prognostic value of coronary vascular endothelial dysfunction. Circulation. 2002;106:653–8.PubMed
23.
Zurück zum Zitat John S, Schmieder RE. Potential mechanisms of impaired endothelial function in arterial hypertension and hypercholesterolemia. Curr Hypertens Rep. 2003;5:199–207.PubMed John S, Schmieder RE. Potential mechanisms of impaired endothelial function in arterial hypertension and hypercholesterolemia. Curr Hypertens Rep. 2003;5:199–207.PubMed
24.
Zurück zum Zitat Schlaich MP, John S, Langenfeld MR, Lackner KJ, Schmitz G, Schmieder RE. Does lipoprotein (a) impair endothelial function? J Am Coll Cardiol. 1998;31:359–65.PubMed Schlaich MP, John S, Langenfeld MR, Lackner KJ, Schmitz G, Schmieder RE. Does lipoprotein (a) impair endothelial function? J Am Coll Cardiol. 1998;31:359–65.PubMed
25.
Zurück zum Zitat Deanfield J, Donald A, Ferri C, et al. Endothelial function and dysfunction. Part I: methodological issues for assessment in the different vascular beds: a statement by the working group on endothelin and endothelial factors of the European society of hypertension. J Hypertens. 2005;23:7–17.PubMed Deanfield J, Donald A, Ferri C, et al. Endothelial function and dysfunction. Part I: methodological issues for assessment in the different vascular beds: a statement by the working group on endothelin and endothelial factors of the European society of hypertension. J Hypertens. 2005;23:7–17.PubMed
26.
Zurück zum Zitat Brevetti G, Silvestro A, Schiano V, Chiariello M. Endothelial dysfunction and cardiovascular risk prediction in peripheral arterial disease: additive value of flow-mediated dilation to ankle-brachial pressure index. Circulation. 2003;108:2093–8.PubMed Brevetti G, Silvestro A, Schiano V, Chiariello M. Endothelial dysfunction and cardiovascular risk prediction in peripheral arterial disease: additive value of flow-mediated dilation to ankle-brachial pressure index. Circulation. 2003;108:2093–8.PubMed
27.
Zurück zum Zitat Chan SY, Mancini GB, Kuramoto L, Schulzer M, Frohlich J, Ignaszewski A. The prognostic importance of endothelial dysfunction and carotid atheroma burden in patients with coronary artery disease. J Am Coll Cardiol. 2003;42:1037–43.PubMed Chan SY, Mancini GB, Kuramoto L, Schulzer M, Frohlich J, Ignaszewski A. The prognostic importance of endothelial dysfunction and carotid atheroma burden in patients with coronary artery disease. J Am Coll Cardiol. 2003;42:1037–43.PubMed
28.
Zurück zum Zitat Guazzi M, Reina G, Gripari P, Tumminello G, Vicenzi M, Arena R. Prognostic value of flow-mediated dilatation following myocardial infarction. Int J Cardiol. 2009;132:45–50.PubMed Guazzi M, Reina G, Gripari P, Tumminello G, Vicenzi M, Arena R. Prognostic value of flow-mediated dilatation following myocardial infarction. Int J Cardiol. 2009;132:45–50.PubMed
29.
Zurück zum Zitat Ross R. Atherosclerosis–an inflammatory disease. N Engl J Med. 1999;340:115–26.PubMed Ross R. Atherosclerosis–an inflammatory disease. N Engl J Med. 1999;340:115–26.PubMed
30.
Zurück zum Zitat McGorisk GM, Treasure CB. Endothelial dysfunction in coronary heart disease. Curr Opin Cardiol. 1996;11:341–50.PubMed McGorisk GM, Treasure CB. Endothelial dysfunction in coronary heart disease. Curr Opin Cardiol. 1996;11:341–50.PubMed
31.
Zurück zum Zitat Pepine CJ. Why vascular biology matters. Am J Cardiol. 2001;88:5K–9K.PubMed Pepine CJ. Why vascular biology matters. Am J Cardiol. 2001;88:5K–9K.PubMed
32.
Zurück zum Zitat Khalil MF, Wagner WD, Goldberg IJ. Molecular interactions leading to lipoprotein retention and the initiation of atherosclerosis. Arterioscler Thromb Vasc Biol. 2004;24:2211–8.PubMed Khalil MF, Wagner WD, Goldberg IJ. Molecular interactions leading to lipoprotein retention and the initiation of atherosclerosis. Arterioscler Thromb Vasc Biol. 2004;24:2211–8.PubMed
33.
Zurück zum Zitat Tousoulis D, Antoniades C, Stefanadis C. Assessing inflammatory status in cardiovascular disease. Heart. 2007;93:1001–7.PubMedCentralPubMed Tousoulis D, Antoniades C, Stefanadis C. Assessing inflammatory status in cardiovascular disease. Heart. 2007;93:1001–7.PubMedCentralPubMed
34.
Zurück zum Zitat Olejarz W, Bryk D, Zapolska-Downar D, Malecki M, Stachurska A, Sitkiewicz D. Mycophenolic acid attenuates the tumour necrosis factor-alpha-mediated proinflammatory response in endothelial cells by blocking the MAPK/NF-kappaB and ROS pathways. Eur J Clin Invest. 2014;44:54–64.PubMed Olejarz W, Bryk D, Zapolska-Downar D, Malecki M, Stachurska A, Sitkiewicz D. Mycophenolic acid attenuates the tumour necrosis factor-alpha-mediated proinflammatory response in endothelial cells by blocking the MAPK/NF-kappaB and ROS pathways. Eur J Clin Invest. 2014;44:54–64.PubMed
35.
Zurück zum Zitat Martinet W, De Meyer GR. Autophagy in atherosclerosis: a cell survival and death phenomenon with therapeutic potential. Circ Res. 2009;104:304–17.PubMed Martinet W, De Meyer GR. Autophagy in atherosclerosis: a cell survival and death phenomenon with therapeutic potential. Circ Res. 2009;104:304–17.PubMed
36.
Zurück zum Zitat Kolodgie FD, Narula J, Burke AP, et al. Localization of apoptotic macrophages at the site of plaque rupture in sudden coronary death. Am J Pathol. 2000;157:1259–68.PubMedCentralPubMed Kolodgie FD, Narula J, Burke AP, et al. Localization of apoptotic macrophages at the site of plaque rupture in sudden coronary death. Am J Pathol. 2000;157:1259–68.PubMedCentralPubMed
37.
Zurück zum Zitat Desideri G, Grassi D, Croce G, et al. Different effects of angiotensin converting enzyme inhibitors on endothelin-1 and nitric oxide balance in human vascular endothelial cells: evidence of an oxidant-sensitive pathway. Mediators Inflamm. 2008;2008:305087.PubMedCentralPubMed Desideri G, Grassi D, Croce G, et al. Different effects of angiotensin converting enzyme inhibitors on endothelin-1 and nitric oxide balance in human vascular endothelial cells: evidence of an oxidant-sensitive pathway. Mediators Inflamm. 2008;2008:305087.PubMedCentralPubMed
38.
Zurück zum Zitat Poss J, Werner C, Lorenz D, Gensch C, Bohm M, Laufs U. The renin inhibitor aliskiren upregulates pro-angiogenic cells and reduces atherogenesis in mice. Basic Res Cardiol. 2010;105:725–35.PubMed Poss J, Werner C, Lorenz D, Gensch C, Bohm M, Laufs U. The renin inhibitor aliskiren upregulates pro-angiogenic cells and reduces atherogenesis in mice. Basic Res Cardiol. 2010;105:725–35.PubMed
39.
Zurück zum Zitat Kobayashi N, Fukushima H, Takeshima H, et al. Effect of eplerenone on endothelial progenitor cells and oxidative stress in ischemic hindlimb. Am J Hypertens. 2010;23:1007–13.PubMed Kobayashi N, Fukushima H, Takeshima H, et al. Effect of eplerenone on endothelial progenitor cells and oxidative stress in ischemic hindlimb. Am J Hypertens. 2010;23:1007–13.PubMed
40.
Zurück zum Zitat Noda K, Kobara M, Hamada J, et al. Additive amelioration of oxidative stress and cardiac function by combined mineralocorticoid and angiotensin receptor blockers in postinfarct failing hearts. J Cardiovasc Pharmacol. 2012;60:140–9.PubMed Noda K, Kobara M, Hamada J, et al. Additive amelioration of oxidative stress and cardiac function by combined mineralocorticoid and angiotensin receptor blockers in postinfarct failing hearts. J Cardiovasc Pharmacol. 2012;60:140–9.PubMed
41.
Zurück zum Zitat Oelze M, Daiber A, Brandes RP, et al. Nebivolol inhibits superoxide formation by NADPH oxidase and endothelial dysfunction in angiotensin II-treated rats. Hypertension. 2006;48:677–84.PubMed Oelze M, Daiber A, Brandes RP, et al. Nebivolol inhibits superoxide formation by NADPH oxidase and endothelial dysfunction in angiotensin II-treated rats. Hypertension. 2006;48:677–84.PubMed
42.
Zurück zum Zitat Hernanz R, Martin A, Perez-Giron JV, et al. Pioglitazone treatment increases COX-2-derived prostacyclin production and reduces oxidative stress in hypertensive rats: role in vascular function. Br J Pharmacol. 2012;166:1303–19.PubMedCentralPubMed Hernanz R, Martin A, Perez-Giron JV, et al. Pioglitazone treatment increases COX-2-derived prostacyclin production and reduces oxidative stress in hypertensive rats: role in vascular function. Br J Pharmacol. 2012;166:1303–19.PubMedCentralPubMed
43.
Zurück zum Zitat Tsai KL, Huang YH, Kao CL, et al. A novel mechanism of coenzyme Q10 protects against human endothelial cells from oxidative stress-induced injury by modulating NO-related pathways. J Nutr Biochem. 2012;23:458–68.PubMed Tsai KL, Huang YH, Kao CL, et al. A novel mechanism of coenzyme Q10 protects against human endothelial cells from oxidative stress-induced injury by modulating NO-related pathways. J Nutr Biochem. 2012;23:458–68.PubMed
44.
Zurück zum Zitat Yang S, Li R, Tang L, et al. TLR4-mediated anti-atherosclerosis mechanisms of angiotensin-converting enzyme inhibitor–fosinopril. Cell Immunol. 2013;285:38–41.PubMed Yang S, Li R, Tang L, et al. TLR4-mediated anti-atherosclerosis mechanisms of angiotensin-converting enzyme inhibitor–fosinopril. Cell Immunol. 2013;285:38–41.PubMed
45.
Zurück zum Zitat Clancy P, Koblar SA, Golledge J. Angiotensin receptor 1 blockade reduces secretion of inflammation associated cytokines from cultured human carotid atheroma and vascular cells in association with reduced extracellular signal regulated kinase expression and activation. Atherosclerosis. 2014;236:108–15.PubMed Clancy P, Koblar SA, Golledge J. Angiotensin receptor 1 blockade reduces secretion of inflammation associated cytokines from cultured human carotid atheroma and vascular cells in association with reduced extracellular signal regulated kinase expression and activation. Atherosclerosis. 2014;236:108–15.PubMed
46.
Zurück zum Zitat Komers R, Simkova R, Kazdova L, Ruzickova J, Pelikanova T. Effects of ACE inhibition and AT1-receptor blockade on haemodynamic responses to L-arginine in type 1 diabetes. J Renin-Angiotensin-Aldosterone Syst: JRAAS. 2004;5:33–8.PubMed Komers R, Simkova R, Kazdova L, Ruzickova J, Pelikanova T. Effects of ACE inhibition and AT1-receptor blockade on haemodynamic responses to L-arginine in type 1 diabetes. J Renin-Angiotensin-Aldosterone Syst: JRAAS. 2004;5:33–8.PubMed
47.
Zurück zum Zitat Schmieder RE, Delles C, Mimran A, Fauvel JP, Ruilope LM. Impact of telmisartan versus ramipril on renal endothelial function in patients with hypertension and type 2 diabetes. Diabetes Care. 2007;30:1351–6.PubMed Schmieder RE, Delles C, Mimran A, Fauvel JP, Ruilope LM. Impact of telmisartan versus ramipril on renal endothelial function in patients with hypertension and type 2 diabetes. Diabetes Care. 2007;30:1351–6.PubMed
48.
Zurück zum Zitat Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The heart outcomes prevention evaluation study investigators. N Engl J Med. 2000;342:145–53.PubMed Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The heart outcomes prevention evaluation study investigators. N Engl J Med. 2000;342:145–53.PubMed
49.
Zurück zum Zitat Pitt B, O'Neill B, Feldman R, et al. The QUinapril ischemic event trial (QUIET): evaluation of chronic ACE inhibitor therapy in patients with ischemic heart disease and preserved left ventricular function. Am J Cardiol. 2001;87:1058–63.PubMed Pitt B, O'Neill B, Feldman R, et al. The QUinapril ischemic event trial (QUIET): evaluation of chronic ACE inhibitor therapy in patients with ischemic heart disease and preserved left ventricular function. Am J Cardiol. 2001;87:1058–63.PubMed
50.
Zurück zum Zitat Schlaifer JD, Wargovich TJ, O'Neill B, et al. Effects of quinapril on coronary blood flow in coronary artery disease patients with endothelial dysfunction. TREND investigators. Trial on reversing endothelial dysfunction. Am J Cardiol. 1997;80:1594–7.PubMed Schlaifer JD, Wargovich TJ, O'Neill B, et al. Effects of quinapril on coronary blood flow in coronary artery disease patients with endothelial dysfunction. TREND investigators. Trial on reversing endothelial dysfunction. Am J Cardiol. 1997;80:1594–7.PubMed
51.
Zurück zum Zitat Pepine CJ. Improved endothelial function with angiotensin-converting enzyme inhibitors. Am J Cardiol. 1997;79:29–32.PubMed Pepine CJ. Improved endothelial function with angiotensin-converting enzyme inhibitors. Am J Cardiol. 1997;79:29–32.PubMed
52.
Zurück zum Zitat Hirohata A, Yamamoto K, Miyoshi T, et al. Impact of olmesartan on progression of coronary atherosclerosis a serial volumetric intravascular ultrasound analysis from the OLIVUS (impact of OLmesarten on progression of coronary atherosclerosis: evaluation by intravascular ultrasound) trial. J Am Coll Cardiol. 2010;55:976–82.PubMed Hirohata A, Yamamoto K, Miyoshi T, et al. Impact of olmesartan on progression of coronary atherosclerosis a serial volumetric intravascular ultrasound analysis from the OLIVUS (impact of OLmesarten on progression of coronary atherosclerosis: evaluation by intravascular ultrasound) trial. J Am Coll Cardiol. 2010;55:976–82.PubMed
53.
Zurück zum Zitat Hirohata A, Yamamoto K, Miyoshi T, et al. Four-year clinical outcomes of the OLIVUS-Ex (impact of Olmesartan on progression of coronary atherosclerosis: evaluation by intravascular ultrasound) extension trial. Atherosclerosis. 2012;220:134–8.PubMed Hirohata A, Yamamoto K, Miyoshi T, et al. Four-year clinical outcomes of the OLIVUS-Ex (impact of Olmesartan on progression of coronary atherosclerosis: evaluation by intravascular ultrasound) extension trial. Atherosclerosis. 2012;220:134–8.PubMed
54.
Zurück zum Zitat Ghiadoni L, Taddei S, Virdis A. Hypertension and endothelial dysfunction: therapeutic approach. Curr Vasc Pharmacol. 2012;10:42–60.PubMed Ghiadoni L, Taddei S, Virdis A. Hypertension and endothelial dysfunction: therapeutic approach. Curr Vasc Pharmacol. 2012;10:42–60.PubMed
55.
Zurück zum Zitat Briasoulis A, Tousoulis D, Androulakis ES, Papageorgiou N, Latsios G, Stefanadis C. Endothelial dysfunction and atherosclerosis: focus on novel therapeutic approaches. Recent Pat Cardiovasc Drug Discov. 2012;7:21–32.PubMed Briasoulis A, Tousoulis D, Androulakis ES, Papageorgiou N, Latsios G, Stefanadis C. Endothelial dysfunction and atherosclerosis: focus on novel therapeutic approaches. Recent Pat Cardiovasc Drug Discov. 2012;7:21–32.PubMed
56.
Zurück zum Zitat Oeseburg H, Iusuf D, van der Harst P, van Gilst WH, Henning RH, Roks AJ. Bradykinin protects against oxidative stress-induced endothelial cell senescence. Hypertension. 2009;53:417–22.PubMed Oeseburg H, Iusuf D, van der Harst P, van Gilst WH, Henning RH, Roks AJ. Bradykinin protects against oxidative stress-induced endothelial cell senescence. Hypertension. 2009;53:417–22.PubMed
57.
Zurück zum Zitat Kobayashi N, Honda T, Yoshida K, et al. Critical role of bradykinin-eNOS and oxidative stress-LOX-1 pathway in cardiovascular remodeling under chronic angiotensin-converting enzyme inhibition. Atherosclerosis. 2006;187:92–100.PubMed Kobayashi N, Honda T, Yoshida K, et al. Critical role of bradykinin-eNOS and oxidative stress-LOX-1 pathway in cardiovascular remodeling under chronic angiotensin-converting enzyme inhibition. Atherosclerosis. 2006;187:92–100.PubMed
58.
Zurück zum Zitat Remme WJ, Deckers JW, Fox KM, et al. Secondary prevention of coronary disease with ACE inhibition–does blood pressure reduction with perindopril explain the benefits in EUROPA? Cardiovasc Drugs Ther Sponsored Int Soc Cardiovasc Pharmacother. 2009;23:161–70. Remme WJ, Deckers JW, Fox KM, et al. Secondary prevention of coronary disease with ACE inhibition–does blood pressure reduction with perindopril explain the benefits in EUROPA? Cardiovasc Drugs Ther Sponsored Int Soc Cardiovasc Pharmacother. 2009;23:161–70.
59.
Zurück zum Zitat Ferrari R, Fox K. Insight into the mode of action of ACE inhibition in coronary artery disease: the ultimate ‘EUROPA’ story. Drugs. 2009;69:265–77.PubMed Ferrari R, Fox K. Insight into the mode of action of ACE inhibition in coronary artery disease: the ultimate ‘EUROPA’ story. Drugs. 2009;69:265–77.PubMed
60.
Zurück zum Zitat Simoons ML, Vos J, de Feyter PJ, et al. EUROPA substudies, confirmation of pathophysiological concepts. European trial on reduction of cardiac events with perindopril in stable coronary artery disease. Eur Heart J. 1998;19:J56–60.PubMed Simoons ML, Vos J, de Feyter PJ, et al. EUROPA substudies, confirmation of pathophysiological concepts. European trial on reduction of cardiac events with perindopril in stable coronary artery disease. Eur Heart J. 1998;19:J56–60.PubMed
61.
Zurück zum Zitat Bots ML, Remme WJ, Luscher TF, et al. ACE inhibition and endothelial function: main findings of PERFECT, a sub-study of the EUROPA trial. Cardiovasc Drugs Ther Sponsored Int Soc Cardiovasc Pharmacother. 2007;21:269–79. Bots ML, Remme WJ, Luscher TF, et al. ACE inhibition and endothelial function: main findings of PERFECT, a sub-study of the EUROPA trial. Cardiovasc Drugs Ther Sponsored Int Soc Cardiovasc Pharmacother. 2007;21:269–79.
62.
Zurück zum Zitat Ceconi C, Francolini G, Bastianon D, Gitti GL, Comini L, Ferrari R. Differences in the effect of angiotensin-converting enzyme inhibitors on the rate of endothelial cell apoptosis: in vitro and in vivo studies. Cardiovasc Drugs Ther Sponsored Int Soc Cardiovasc Pharmacother. 2007;21:423–9. Ceconi C, Francolini G, Bastianon D, Gitti GL, Comini L, Ferrari R. Differences in the effect of angiotensin-converting enzyme inhibitors on the rate of endothelial cell apoptosis: in vitro and in vivo studies. Cardiovasc Drugs Ther Sponsored Int Soc Cardiovasc Pharmacother. 2007;21:423–9.
63.
Zurück zum Zitat Remme WJ. Secondary prevention of coronary artery disease and the choice of the ACE inhibitor why EUROPA and not PEACE. Cardiovasc Drugs Ther Sponsored Int Soc Cardiovasc Pharmacother. 2007;21:405–7. Remme WJ. Secondary prevention of coronary artery disease and the choice of the ACE inhibitor why EUROPA and not PEACE. Cardiovasc Drugs Ther Sponsored Int Soc Cardiovasc Pharmacother. 2007;21:405–7.
64.
Zurück zum Zitat Fliser D, Buchholz K, Haller H. Olmesartan EUTo, Pravastatin in I, Atherosclerosis I. Antiinflammatory effects of angiotensin II subtype 1 receptor blockade in hypertensive patients with microinflammation. Circulation. 2004;110:1103–7.PubMed Fliser D, Buchholz K, Haller H. Olmesartan EUTo, Pravastatin in I, Atherosclerosis I. Antiinflammatory effects of angiotensin II subtype 1 receptor blockade in hypertensive patients with microinflammation. Circulation. 2004;110:1103–7.PubMed
65.
Zurück zum Zitat Mason RP. Optimal therapeutic strategy for treating patients with hypertension and atherosclerosis: focus on olmesartan medoxomil. Vasc Health Risk Manag. 2011;7:405–16.PubMedCentralPubMed Mason RP. Optimal therapeutic strategy for treating patients with hypertension and atherosclerosis: focus on olmesartan medoxomil. Vasc Health Risk Manag. 2011;7:405–16.PubMedCentralPubMed
66.
Zurück zum Zitat Stumpe KO, Agabiti-Rosei E, Zielinski T, et al. Carotid intima-media thickness and plaque volume changes following 2-year angiotensin II-receptor blockade. The multicentre olmesartan atherosclerosis regression evaluation (MORE) study. Ther Adv Cardiovasc Dis. 2007;1:97–106.PubMed Stumpe KO, Agabiti-Rosei E, Zielinski T, et al. Carotid intima-media thickness and plaque volume changes following 2-year angiotensin II-receptor blockade. The multicentre olmesartan atherosclerosis regression evaluation (MORE) study. Ther Adv Cardiovasc Dis. 2007;1:97–106.PubMed
67.
Zurück zum Zitat Tzemos N, Lim PO, MacDonald TM. Valsartan improves endothelial dysfunction in hypertension: a randomized, double-blind study. Cardiovasc Ther. 2009;27:151–8.PubMedCentralPubMed Tzemos N, Lim PO, MacDonald TM. Valsartan improves endothelial dysfunction in hypertension: a randomized, double-blind study. Cardiovasc Ther. 2009;27:151–8.PubMedCentralPubMed
68.
Zurück zum Zitat Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. The SOLVD Investigators. N Engl J Med 1991;325:293–302. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. The SOLVD Investigators. N Engl J Med 1991;325:293–302.
69.
Zurück zum Zitat Patel A, Group AC, MacMahon S, et al. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomized controlled trial. Lancet. 2007;370:829–40.PubMed Patel A, Group AC, MacMahon S, et al. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomized controlled trial. Lancet. 2007;370:829–40.PubMed
70.
Zurück zum Zitat ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The antihypertensive and lipid-lowering treatment to prevent heart attack trial. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). JAMA. 2002;288:2981–97. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The antihypertensive and lipid-lowering treatment to prevent heart attack trial. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). JAMA. 2002;288:2981–97.
71.
Zurück zum Zitat Task Force M, Montalescot G, Sechtem U, et al. 2013 ESC guidelines on the management of stable coronary artery disease: the task force on the management of stable coronary artery disease of the European society of cardiology. Eur Heart J. 2013;34:2949–3003. Task Force M, Montalescot G, Sechtem U, et al. 2013 ESC guidelines on the management of stable coronary artery disease: the task force on the management of stable coronary artery disease of the European society of cardiology. Eur Heart J. 2013;34:2949–3003.
72.
Zurück zum Zitat Yamamoto E, Kataoka K, Dong YF, et al. Aliskiren enhances the protective effects of valsartan against cardiovascular and renal injury in endothelial nitric oxide synthase-deficient mice. Hypertension. 2009;54:633–8.PubMed Yamamoto E, Kataoka K, Dong YF, et al. Aliskiren enhances the protective effects of valsartan against cardiovascular and renal injury in endothelial nitric oxide synthase-deficient mice. Hypertension. 2009;54:633–8.PubMed
73.
Zurück zum Zitat Harel Z, Gilbert C, Wald R, et al. The effect of combination treatment with aliskiren and blockers of the renin-angiotensin system on hyperkalaemia and acute kidney injury: systematic review and meta-analysis. BMJ. 2012;344:e42.PubMedCentralPubMed Harel Z, Gilbert C, Wald R, et al. The effect of combination treatment with aliskiren and blockers of the renin-angiotensin system on hyperkalaemia and acute kidney injury: systematic review and meta-analysis. BMJ. 2012;344:e42.PubMedCentralPubMed
74.
Zurück zum Zitat Maffei A, Lembo G. Nitric oxide mechanisms of nebivolol. Ther Adv Cardiovasc Dis. 2009;3:317–27.PubMed Maffei A, Lembo G. Nitric oxide mechanisms of nebivolol. Ther Adv Cardiovasc Dis. 2009;3:317–27.PubMed
75.
Zurück zum Zitat Pasini AF, Garbin U, Stranieri C, et al. Nebivolol treatment reduces serum levels of asymmetric dimethylarginine and improves endothelial dysfunction in essential hypertensive patients. Am J Hypertens. 2008;21:1251–7.PubMed Pasini AF, Garbin U, Stranieri C, et al. Nebivolol treatment reduces serum levels of asymmetric dimethylarginine and improves endothelial dysfunction in essential hypertensive patients. Am J Hypertens. 2008;21:1251–7.PubMed
76.
Zurück zum Zitat Merchant N, Searles CD, Pandian A, et al. Nebivolol in high-risk, obese African Americans with stage 1 hypertension: effects on blood pressure, vascular compliance, and endothelial function. J Clin Hypertens (Greenwich). 2009;11:720–5. Merchant N, Searles CD, Pandian A, et al. Nebivolol in high-risk, obese African Americans with stage 1 hypertension: effects on blood pressure, vascular compliance, and endothelial function. J Clin Hypertens (Greenwich). 2009;11:720–5.
77.
Zurück zum Zitat Evangelista S, Garbin U, Pasini AF, Stranieri C, Boccioletti V, Cominacini L. Effect of DL-nebivolol, its enantiomers and metabolites on the intracellular production of superoxide and nitric oxide in human endothelial cells. Pharmacol Res. 2007;55:303–9.PubMed Evangelista S, Garbin U, Pasini AF, Stranieri C, Boccioletti V, Cominacini L. Effect of DL-nebivolol, its enantiomers and metabolites on the intracellular production of superoxide and nitric oxide in human endothelial cells. Pharmacol Res. 2007;55:303–9.PubMed
78.
Zurück zum Zitat Akcay A, Acar G, Kurutas E, et al. Beneficial effects of nebivolol treatment on oxidative stress parameters in patients with slow coronary flow. Turk Kardiyol Dern Ars. 2010;38:244–9.PubMed Akcay A, Acar G, Kurutas E, et al. Beneficial effects of nebivolol treatment on oxidative stress parameters in patients with slow coronary flow. Turk Kardiyol Dern Ars. 2010;38:244–9.PubMed
79.
Zurück zum Zitat Gao WQ, Feng QZ, Li YF, et al. Systematic study of the effects of lowering low-density lipoprotein-cholesterol on regression of coronary atherosclerotic plaques using intravascular ultrasound. BMC Cardiovasc Disord. 2014;14:60.PubMedCentralPubMed Gao WQ, Feng QZ, Li YF, et al. Systematic study of the effects of lowering low-density lipoprotein-cholesterol on regression of coronary atherosclerotic plaques using intravascular ultrasound. BMC Cardiovasc Disord. 2014;14:60.PubMedCentralPubMed
80.
Zurück zum Zitat Tousoulis D, Oikonomou E, Siasos G, et al. Dose-dependent effects of short term atorvastatin treatment on arterial wall properties and on indices of left ventricular remodeling in ischemic heart failure. Atherosclerosis. 2013;227:367–72.PubMed Tousoulis D, Oikonomou E, Siasos G, et al. Dose-dependent effects of short term atorvastatin treatment on arterial wall properties and on indices of left ventricular remodeling in ischemic heart failure. Atherosclerosis. 2013;227:367–72.PubMed
81.
Zurück zum Zitat Wassmann S, Nickenig G. Interrelationship of free oxygen radicals and endothelial dysfunction–modulation by statins. Endothelium. 2003;10:23–33.PubMed Wassmann S, Nickenig G. Interrelationship of free oxygen radicals and endothelial dysfunction–modulation by statins. Endothelium. 2003;10:23–33.PubMed
82.
83.
Zurück zum Zitat Inoue T, Takayanagi K, Hayashi T, Morooka S. Fluvastatin attenuates nitrate tolerance in patients with ischemic heart disease complicating hypercholesterolemia. Int J Cardiol. 2003;90:181–8.PubMed Inoue T, Takayanagi K, Hayashi T, Morooka S. Fluvastatin attenuates nitrate tolerance in patients with ischemic heart disease complicating hypercholesterolemia. Int J Cardiol. 2003;90:181–8.PubMed
84.
Zurück zum Zitat Milionis HJ, Liberopoulos EN, Elisaf MS, Mikhailidis DP. Analysis of antihypertensive effects of statins. Curr Hypertens Rep. 2007;9:175–83.PubMed Milionis HJ, Liberopoulos EN, Elisaf MS, Mikhailidis DP. Analysis of antihypertensive effects of statins. Curr Hypertens Rep. 2007;9:175–83.PubMed
85.
Zurück zum Zitat Nohara R, Daida H, Hata M, et al. Effect of intensive lipid-lowering therapy with rosuvastatin on progression of carotid intima-media thickness in Japanese patients: justification for atherosclerosis regression treatment (JART) study. Circ J. 2012;76:221–9.PubMed Nohara R, Daida H, Hata M, et al. Effect of intensive lipid-lowering therapy with rosuvastatin on progression of carotid intima-media thickness in Japanese patients: justification for atherosclerosis regression treatment (JART) study. Circ J. 2012;76:221–9.PubMed
86.
Zurück zum Zitat Kovarnik T, Mintz GS, Skalicka H, et al. Virtual histology evaluation of atherosclerosis regression during atorvastatin and ezetimibe administration: HEAVEN study. Circ J. 2012;76:176–83.PubMed Kovarnik T, Mintz GS, Skalicka H, et al. Virtual histology evaluation of atherosclerosis regression during atorvastatin and ezetimibe administration: HEAVEN study. Circ J. 2012;76:176–83.PubMed
87.
Zurück zum Zitat Schwartz GG, Olsson AG, Ezekowitz MD, et al. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA. 2001;285:1711–8.PubMed Schwartz GG, Olsson AG, Ezekowitz MD, et al. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA. 2001;285:1711–8.PubMed
88.
Zurück zum Zitat Kim JS, Kim J, Choi D, et al. Efficacy of high-dose atorvastatin loading before primary percutaneous coronary intervention in ST-segment elevation myocardial infarction: the STATIN STEMI trial. JACC Cardiovasc Interv. 2010;3:332–9.PubMed Kim JS, Kim J, Choi D, et al. Efficacy of high-dose atorvastatin loading before primary percutaneous coronary intervention in ST-segment elevation myocardial infarction: the STATIN STEMI trial. JACC Cardiovasc Interv. 2010;3:332–9.PubMed
89.
Zurück zum Zitat Ostadal P, Alan D, Vejvoda J, et al. Fluvastatin in the first-line therapy of acute coronary syndrome: results of the multicenter, randomized, double-blind, placebo-controlled trial (the FACS-trial). Trials. 2010;11:61.PubMedCentralPubMed Ostadal P, Alan D, Vejvoda J, et al. Fluvastatin in the first-line therapy of acute coronary syndrome: results of the multicenter, randomized, double-blind, placebo-controlled trial (the FACS-trial). Trials. 2010;11:61.PubMedCentralPubMed
90.
Zurück zum Zitat Jackson SM, Parhami F, Xi XP, et al. Peroxisome proliferator-activated receptor activators target human endothelial cells to inhibit leukocyte-endothelial cell interaction. Arterioscler Thromb Vasc Biol. 1999;19:2094–104.PubMed Jackson SM, Parhami F, Xi XP, et al. Peroxisome proliferator-activated receptor activators target human endothelial cells to inhibit leukocyte-endothelial cell interaction. Arterioscler Thromb Vasc Biol. 1999;19:2094–104.PubMed
91.
Zurück zum Zitat Calnek DS, Mazzella L, Roser S, Roman J, Hart CM. Peroxisome proliferator-activated receptor gamma ligands increase release of nitric oxide from endothelial cells. Arterioscler Thromb Vasc Biol. 2003;23:52–7.PubMed Calnek DS, Mazzella L, Roser S, Roman J, Hart CM. Peroxisome proliferator-activated receptor gamma ligands increase release of nitric oxide from endothelial cells. Arterioscler Thromb Vasc Biol. 2003;23:52–7.PubMed
92.
Zurück zum Zitat Hwang J, Kleinhenz DJ, Lassegue B, Griendling KK, Dikalov S, Hart CM. Peroxisome proliferator-activated receptor-gamma ligands regulate endothelial membrane superoxide production. Am J Physiol Cell Physiol. 2005;288:C899–905.PubMed Hwang J, Kleinhenz DJ, Lassegue B, Griendling KK, Dikalov S, Hart CM. Peroxisome proliferator-activated receptor-gamma ligands regulate endothelial membrane superoxide production. Am J Physiol Cell Physiol. 2005;288:C899–905.PubMed
93.
Zurück zum Zitat Faine LA, Rudnicki M, Cesar FA, et al. Anti-inflammatory and antioxidant properties of a new arylidene-thiazolidinedione in macrophages. Curr Med Chem. 2011;18:3351–60.PubMed Faine LA, Rudnicki M, Cesar FA, et al. Anti-inflammatory and antioxidant properties of a new arylidene-thiazolidinedione in macrophages. Curr Med Chem. 2011;18:3351–60.PubMed
94.
Zurück zum Zitat van Wijk JP, Rabelink TJ. Impact of thiazolidinedione therapy on atherogenesis. Curr Atheroscler Rep. 2005;7:369–74.PubMed van Wijk JP, Rabelink TJ. Impact of thiazolidinedione therapy on atherogenesis. Curr Atheroscler Rep. 2005;7:369–74.PubMed
95.
Zurück zum Zitat Houston M, Estevez A, Chumley P, et al. Binding of xanthine oxidase to vascular endothelium. Kinetic characterization and oxidative impairment of nitric oxide-dependent signaling. J Biol Chem. 1999;274:4985–94.PubMed Houston M, Estevez A, Chumley P, et al. Binding of xanthine oxidase to vascular endothelium. Kinetic characterization and oxidative impairment of nitric oxide-dependent signaling. J Biol Chem. 1999;274:4985–94.PubMed
96.
Zurück zum Zitat Higgins P, Dawson J, Lees KR, McArthur K, Quinn TJ, Walters MR. Xanthine oxidase inhibition for the treatment of cardiovascular disease: a systematic review and meta-analysis. Cardiovasc Ther. 2012;30:217–26.PubMed Higgins P, Dawson J, Lees KR, McArthur K, Quinn TJ, Walters MR. Xanthine oxidase inhibition for the treatment of cardiovascular disease: a systematic review and meta-analysis. Cardiovasc Ther. 2012;30:217–26.PubMed
97.
Zurück zum Zitat Mercuro G, Vitale C, Cerquetani E, et al. Effect of hyperuricemia upon endothelial function in patients at increased cardiovascular risk. Am J Cardiol. 2004;94:932–5.PubMed Mercuro G, Vitale C, Cerquetani E, et al. Effect of hyperuricemia upon endothelial function in patients at increased cardiovascular risk. Am J Cardiol. 2004;94:932–5.PubMed
98.
Zurück zum Zitat Baldus S, Koster R, Chumley P, et al. Oxypurinol improves coronary and peripheral endothelial function in patients with coronary artery disease. Free Radic Biol Med. 2005;39:1184–90.PubMedCentralPubMed Baldus S, Koster R, Chumley P, et al. Oxypurinol improves coronary and peripheral endothelial function in patients with coronary artery disease. Free Radic Biol Med. 2005;39:1184–90.PubMedCentralPubMed
99.
Zurück zum Zitat Tousoulis D, Andreou I, Tsiatas M, et al. Effects of rosuvastatin and allopurinol on circulating endothelial progenitor cells in patients with congestive heart failure: the impact of inflammatory process and oxidative stress. Atherosclerosis. 2011;214:151–7.PubMed Tousoulis D, Andreou I, Tsiatas M, et al. Effects of rosuvastatin and allopurinol on circulating endothelial progenitor cells in patients with congestive heart failure: the impact of inflammatory process and oxidative stress. Atherosclerosis. 2011;214:151–7.PubMed
100.
Zurück zum Zitat Werner ER, Blau N, Thony B. Tetrahydrobiopterin: biochemistry and pathophysiology. Biochem J. 2011;438:397–414.PubMed Werner ER, Blau N, Thony B. Tetrahydrobiopterin: biochemistry and pathophysiology. Biochem J. 2011;438:397–414.PubMed
101.
Zurück zum Zitat Cunnington C, Channon KM. Tetrahydrobiopterin: pleiotropic roles in cardiovascular pathophysiology. Heart. 2010;96:1872–7.PubMed Cunnington C, Channon KM. Tetrahydrobiopterin: pleiotropic roles in cardiovascular pathophysiology. Heart. 2010;96:1872–7.PubMed
102.
Zurück zum Zitat Vasquez-Vivar J, Kalyanaraman B, Martasek P. The role of tetrahydrobiopterin in superoxide generation from eNOS: enzymology and physiological implications. Free Radic Res. 2003;37:121–7.PubMed Vasquez-Vivar J, Kalyanaraman B, Martasek P. The role of tetrahydrobiopterin in superoxide generation from eNOS: enzymology and physiological implications. Free Radic Res. 2003;37:121–7.PubMed
103.
Zurück zum Zitat Bendall JK, Douglas G, McNeill E, Channon KM, Crabtree MJ. Tetrahydrobiopterin in cardiovascular health and disease. Antioxidants Redox Signaling. 2014;20:3040–77.PubMedCentralPubMed Bendall JK, Douglas G, McNeill E, Channon KM, Crabtree MJ. Tetrahydrobiopterin in cardiovascular health and disease. Antioxidants Redox Signaling. 2014;20:3040–77.PubMedCentralPubMed
104.
Zurück zum Zitat Tiefenbacher CP, Bleeke T, Vahl C, Amann K, Vogt A, Kubler W. Endothelial dysfunction of coronary resistance arteries is improved by tetrahydrobiopterin in atherosclerosis. Circulation. 2000;102:2172–9.PubMed Tiefenbacher CP, Bleeke T, Vahl C, Amann K, Vogt A, Kubler W. Endothelial dysfunction of coronary resistance arteries is improved by tetrahydrobiopterin in atherosclerosis. Circulation. 2000;102:2172–9.PubMed
105.
Zurück zum Zitat Hattori Y, Hattori S, Wang X, Satoh H, Nakanishi N, Kasai K. Oral administration of tetrahydrobiopterin slows the progression of atherosclerosis in apolipoprotein E-knockout mice. Arterioscler Thromb Vasc Biol. 2007;27:865–70.PubMed Hattori Y, Hattori S, Wang X, Satoh H, Nakanishi N, Kasai K. Oral administration of tetrahydrobiopterin slows the progression of atherosclerosis in apolipoprotein E-knockout mice. Arterioscler Thromb Vasc Biol. 2007;27:865–70.PubMed
106.
Zurück zum Zitat Cosentino F, Hurlimann D, Delli Gatti C, et al. Chronic treatment with tetrahydrobiopterin reverses endothelial dysfunction and oxidative stress in hypercholesterolaemia. Heart. 2008;94:487–92.PubMed Cosentino F, Hurlimann D, Delli Gatti C, et al. Chronic treatment with tetrahydrobiopterin reverses endothelial dysfunction and oxidative stress in hypercholesterolaemia. Heart. 2008;94:487–92.PubMed
107.
Zurück zum Zitat Wenzel P, Schulz E, Oelze M, et al. AT1-receptor blockade by telmisartan upregulates GTP-cyclohydrolase I and protects eNOS in diabetic rats. Free Radic Biol Med. 2008;45:619–26.PubMed Wenzel P, Schulz E, Oelze M, et al. AT1-receptor blockade by telmisartan upregulates GTP-cyclohydrolase I and protects eNOS in diabetic rats. Free Radic Biol Med. 2008;45:619–26.PubMed
108.
Zurück zum Zitat Pashkow FJ. Oxidative stress and inflammation in heart disease: do antioxidants have a role in treatment and/or prevention? Int J Inflam. 2011;2011:514623.PubMedCentralPubMed Pashkow FJ. Oxidative stress and inflammation in heart disease: do antioxidants have a role in treatment and/or prevention? Int J Inflam. 2011;2011:514623.PubMedCentralPubMed
109.
Zurück zum Zitat Carr AC, Zhu BZ, Frei B. Potential antiatherogenic mechanisms of ascorbate (vitamin C) and alpha-tocopherol (vitamin E). Circ Res. 2000;87:349–54.PubMed Carr AC, Zhu BZ, Frei B. Potential antiatherogenic mechanisms of ascorbate (vitamin C) and alpha-tocopherol (vitamin E). Circ Res. 2000;87:349–54.PubMed
110.
Zurück zum Zitat Padayatty SJ, Katz A, Wang Y, et al. Vitamin C as an antioxidant: evaluation of its role in disease prevention. J Am Coll Nutr. 2003;22:18–35.PubMed Padayatty SJ, Katz A, Wang Y, et al. Vitamin C as an antioxidant: evaluation of its role in disease prevention. J Am Coll Nutr. 2003;22:18–35.PubMed
111.
Zurück zum Zitat Paravicini TM, Touyz RM. NADPH oxidases, reactive oxygen species, and hypertension: clinical implications and therapeutic possibilities. Diabetes Care. 2008;31(2):S170–80.PubMed Paravicini TM, Touyz RM. NADPH oxidases, reactive oxygen species, and hypertension: clinical implications and therapeutic possibilities. Diabetes Care. 2008;31(2):S170–80.PubMed
112.
Zurück zum Zitat Plantinga Y, Ghiadoni L, Magagna A, et al. Supplementation with vitamins C and E improves arterial stiffness and endothelial function in essential hypertensive patients. Am J Hypertens. 2007;20:392–7.PubMed Plantinga Y, Ghiadoni L, Magagna A, et al. Supplementation with vitamins C and E improves arterial stiffness and endothelial function in essential hypertensive patients. Am J Hypertens. 2007;20:392–7.PubMed
113.
Zurück zum Zitat Tousoulis D, Antoniades C, Tentolouris C, et al. Effects of combined administration of vitamins C and E on reactive hyperemia and inflammatory process in chronic smokers. Atherosclerosis. 2003;170:261–7.PubMed Tousoulis D, Antoniades C, Tentolouris C, et al. Effects of combined administration of vitamins C and E on reactive hyperemia and inflammatory process in chronic smokers. Atherosclerosis. 2003;170:261–7.PubMed
114.
Zurück zum Zitat Antoniades C, Tousoulis D, Tentolouris C, et al. Effects of antioxidant vitamins C and E on endothelial function and thrombosis/fibrinolysis system in smokers. Thromb Haemost. 2003;89:990–5.PubMed Antoniades C, Tousoulis D, Tentolouris C, et al. Effects of antioxidant vitamins C and E on endothelial function and thrombosis/fibrinolysis system in smokers. Thromb Haemost. 2003;89:990–5.PubMed
115.
Zurück zum Zitat Stephens NG, Parsons A, Schofield PM, Kelly F, Cheeseman K, Mitchinson MJ. Randomised controlled trial of vitamin E in patients with coronary disease: cambridge heart antioxidant study (CHAOS). Lancet. 1996;347:781–6.PubMed Stephens NG, Parsons A, Schofield PM, Kelly F, Cheeseman K, Mitchinson MJ. Randomised controlled trial of vitamin E in patients with coronary disease: cambridge heart antioxidant study (CHAOS). Lancet. 1996;347:781–6.PubMed
116.
Zurück zum Zitat Bleys J, Miller 3rd ER, Pastor-Barriuso R, Appel LJ, Guallar E. Vitamin-mineral supplementation and the progression of atherosclerosis: a meta-analysis of randomized controlled trials. Am J Clin Nutr. 2006;84:880–7. quiz 954–5.PubMed Bleys J, Miller 3rd ER, Pastor-Barriuso R, Appel LJ, Guallar E. Vitamin-mineral supplementation and the progression of atherosclerosis: a meta-analysis of randomized controlled trials. Am J Clin Nutr. 2006;84:880–7. quiz 954–5.PubMed
117.
Zurück zum Zitat Sesso HD, Buring JE, Christen WG, et al. Vitamins E and C in the prevention of cardiovascular disease in men: the physicians’ health study II randomized controlled trial. JAMA. 2008;300:2123–33.PubMedCentralPubMed Sesso HD, Buring JE, Christen WG, et al. Vitamins E and C in the prevention of cardiovascular disease in men: the physicians’ health study II randomized controlled trial. JAMA. 2008;300:2123–33.PubMedCentralPubMed
118.
Zurück zum Zitat Cook NR, Albert CM, Gaziano JM, et al. A randomized factorial trial of vitamins C and E and beta carotene in the secondary prevention of cardiovascular events in women: results from the women’s antioxidant cardiovascular study. Arch Intern Med. 2007;167:1610–8.PubMedCentralPubMed Cook NR, Albert CM, Gaziano JM, et al. A randomized factorial trial of vitamins C and E and beta carotene in the secondary prevention of cardiovascular events in women: results from the women’s antioxidant cardiovascular study. Arch Intern Med. 2007;167:1610–8.PubMedCentralPubMed
119.
Zurück zum Zitat Bonaa KH, Njolstad I, Ueland PM, et al. Homocysteine lowering and cardiovascular events after acute myocardial infarction. N Engl J Med. 2006;354:1578–88.PubMed Bonaa KH, Njolstad I, Ueland PM, et al. Homocysteine lowering and cardiovascular events after acute myocardial infarction. N Engl J Med. 2006;354:1578–88.PubMed
120.
Zurück zum Zitat Till U, Rohl P, Jentsch A, et al. Decrease of carotid intima-media thickness in patients at risk to cerebral ischemia after supplementation with folic acid, vitamins B6 and B12. Atherosclerosis. 2005;181:131–5.PubMed Till U, Rohl P, Jentsch A, et al. Decrease of carotid intima-media thickness in patients at risk to cerebral ischemia after supplementation with folic acid, vitamins B6 and B12. Atherosclerosis. 2005;181:131–5.PubMed
121.
Zurück zum Zitat Antoniades C, Antonopoulos AS, Tousoulis D, Marinou K, Stefanadis C. Homocysteine and coronary atherosclerosis: from folate fortification to the recent clinical trials. Eur Heart J. 2009;30:6–15.PubMed Antoniades C, Antonopoulos AS, Tousoulis D, Marinou K, Stefanadis C. Homocysteine and coronary atherosclerosis: from folate fortification to the recent clinical trials. Eur Heart J. 2009;30:6–15.PubMed
122.
Zurück zum Zitat Antoniades C, Shirodaria C, Warrick N, et al. 5-methyltetrahydrofolate rapidly improves endothelial function and decreases superoxide production in human vessels: effects on vascular tetrahydrobiopterin availability and endothelial nitric oxide synthase coupling. Circulation. 2006;114:1193–201.PubMed Antoniades C, Shirodaria C, Warrick N, et al. 5-methyltetrahydrofolate rapidly improves endothelial function and decreases superoxide production in human vessels: effects on vascular tetrahydrobiopterin availability and endothelial nitric oxide synthase coupling. Circulation. 2006;114:1193–201.PubMed
123.
Zurück zum Zitat Toole JF, Malinow MR, Chambless LE, et al. Lowering homocysteine in patients with ischemic stroke to prevent recurrent stroke, myocardial infarction, and death: the vitamin intervention for stroke prevention (VISP) randomized controlled trial. JAMA. 2004;291:565–75.PubMed Toole JF, Malinow MR, Chambless LE, et al. Lowering homocysteine in patients with ischemic stroke to prevent recurrent stroke, myocardial infarction, and death: the vitamin intervention for stroke prevention (VISP) randomized controlled trial. JAMA. 2004;291:565–75.PubMed
124.
Zurück zum Zitat Gissi HFI, Tavazzi L, Maggioni AP, et al. Effect of n-3 polyunsaturated fatty acids in patients with chronic heart failure (the GISSI-HF trial): a randomized, double-blind, placebo-controlled trial. Lancet. 2008;372:1223–30. Gissi HFI, Tavazzi L, Maggioni AP, et al. Effect of n-3 polyunsaturated fatty acids in patients with chronic heart failure (the GISSI-HF trial): a randomized, double-blind, placebo-controlled trial. Lancet. 2008;372:1223–30.
125.
Zurück zum Zitat Wang Q, Liang X, Wang L, et al. Effect of omega-3 fatty acids supplementation on endothelial function: a meta-analysis of randomized controlled trials. Atherosclerosis. 2012;221:536–43.PubMed Wang Q, Liang X, Wang L, et al. Effect of omega-3 fatty acids supplementation on endothelial function: a meta-analysis of randomized controlled trials. Atherosclerosis. 2012;221:536–43.PubMed
126.
Zurück zum Zitat Miller 3rd ER, Juraschek SP, Anderson CA, et al. The effects of n-3 long-chain polyunsaturated fatty acid supplementation on biomarkers of kidney injury in adults with diabetes: results of the GO-FISH trial. Diabetes Care. 2013;36:1462–9.PubMedCentralPubMed Miller 3rd ER, Juraschek SP, Anderson CA, et al. The effects of n-3 long-chain polyunsaturated fatty acid supplementation on biomarkers of kidney injury in adults with diabetes: results of the GO-FISH trial. Diabetes Care. 2013;36:1462–9.PubMedCentralPubMed
127.
Zurück zum Zitat Tousoulis D, Plastiras A, Siasos G, et al. Omega-3 PUFAs improved endothelial function and arterial stiffness with a parallel antiinflammatory effect in adults with metabolic syndrome. Atherosclerosis. 2014;232:10–6.PubMed Tousoulis D, Plastiras A, Siasos G, et al. Omega-3 PUFAs improved endothelial function and arterial stiffness with a parallel antiinflammatory effect in adults with metabolic syndrome. Atherosclerosis. 2014;232:10–6.PubMed
128.
Zurück zum Zitat Siasos G, Tousoulis D, Oikonomou E, et al. Effects of Omega-3 fatty acids on endothelial function, arterial wall properties, inflammatory and fibrinolytic status in smokers: a cross over study. Int J Cardiol. 2013;166:340–6.PubMed Siasos G, Tousoulis D, Oikonomou E, et al. Effects of Omega-3 fatty acids on endothelial function, arterial wall properties, inflammatory and fibrinolytic status in smokers: a cross over study. Int J Cardiol. 2013;166:340–6.PubMed
129.
Zurück zum Zitat Das UN. Long-chain polyunsaturated fatty acids interact with nitric oxide, superoxide anion, and transforming growth factor-beta to prevent human essential hypertension. Eur J Clin Nutr. 2004;58:195–203.PubMed Das UN. Long-chain polyunsaturated fatty acids interact with nitric oxide, superoxide anion, and transforming growth factor-beta to prevent human essential hypertension. Eur J Clin Nutr. 2004;58:195–203.PubMed
130.
Zurück zum Zitat Saravanan P, Davidson NC, Schmidt EB, Calder PC. Cardiovascular effects of marine omega-3 fatty acids. Lancet. 2010;376:540–50.PubMed Saravanan P, Davidson NC, Schmidt EB, Calder PC. Cardiovascular effects of marine omega-3 fatty acids. Lancet. 2010;376:540–50.PubMed
131.
Zurück zum Zitat Guermouche B, Soulimane-Mokhtari NA, Bouanane S, Merzouk H, Merzouk S, Narce M. Effect of dietary N - 3 polyunsaturated Fatty acids on oxidant/antioxidant status in macrosomic offspring of diabetic rats. BioMed Res Intern. 2014;2014:368107. Guermouche B, Soulimane-Mokhtari NA, Bouanane S, Merzouk H, Merzouk S, Narce M. Effect of dietary N - 3 polyunsaturated Fatty acids on oxidant/antioxidant status in macrosomic offspring of diabetic rats. BioMed Res Intern. 2014;2014:368107.
132.
Zurück zum Zitat Richard D, Kefi K, Barbe U, Bausero P, Visioli F. Polyunsaturated fatty acids as antioxidants. Pharmacol Res: Off J Ital Pharmacol Soc. 2008;57:451–5. Richard D, Kefi K, Barbe U, Bausero P, Visioli F. Polyunsaturated fatty acids as antioxidants. Pharmacol Res: Off J Ital Pharmacol Soc. 2008;57:451–5.
133.
Zurück zum Zitat Hassan Eftekhari M, Aliasghari F, Babaei-Beigi MA, Hasanzadeh J. Effect of conjugated linoleic acid and omega-3 fatty acid supplementation on inflammatory and oxidative stress markers in atherosclerotic patients. ARYA atherosclerosis. 2013;9:311–8.PubMedCentralPubMed Hassan Eftekhari M, Aliasghari F, Babaei-Beigi MA, Hasanzadeh J. Effect of conjugated linoleic acid and omega-3 fatty acid supplementation on inflammatory and oxidative stress markers in atherosclerotic patients. ARYA atherosclerosis. 2013;9:311–8.PubMedCentralPubMed
134.
Zurück zum Zitat Lee LK, Shahar S, Rajab N, Yusoff NA, Jamal RA, Then SM. The role of long chain omega-3 polyunsaturated fatty acids in reducing lipid peroxidation among elderly patients with mild cognitive impairment: a case–control study. J Nutr Biochem. 2013;24:803–8.PubMed Lee LK, Shahar S, Rajab N, Yusoff NA, Jamal RA, Then SM. The role of long chain omega-3 polyunsaturated fatty acids in reducing lipid peroxidation among elderly patients with mild cognitive impairment: a case–control study. J Nutr Biochem. 2013;24:803–8.PubMed
135.
Zurück zum Zitat Mukamal KJ, Conigrave KM, Mittleman MA, et al. Roles of drinking pattern and type of alcohol consumed in coronary heart disease in men. N Engl J Med. 2003;348:109–18.PubMed Mukamal KJ, Conigrave KM, Mittleman MA, et al. Roles of drinking pattern and type of alcohol consumed in coronary heart disease in men. N Engl J Med. 2003;348:109–18.PubMed
136.
Zurück zum Zitat Ivey KL, Lewis JR, Prince RL, Hodgson JM. Tea and non-tea flavonol intakes in relation to atherosclerotic vascular disease mortality in older women. Br J Nut. 2013;110:1648–55. Ivey KL, Lewis JR, Prince RL, Hodgson JM. Tea and non-tea flavonol intakes in relation to atherosclerotic vascular disease mortality in older women. Br J Nut. 2013;110:1648–55.
137.
Zurück zum Zitat Pandey KB, Rizvi SI. Plant polyphenols as dietary antioxidants in human health and disease. Oxid Med Cell Longev. 2009;2:270–8.PubMedCentralPubMed Pandey KB, Rizvi SI. Plant polyphenols as dietary antioxidants in human health and disease. Oxid Med Cell Longev. 2009;2:270–8.PubMedCentralPubMed
138.
Zurück zum Zitat Okawa M, Kinjo J, Nohara T, Ono M. DPPH (1,1-diphenyl-2-picrylhydrazyl) radical scavenging activity of flavonoids obtained from some medicinal plants. Biol Pharm Bull. 2001;24:1202–5.PubMed Okawa M, Kinjo J, Nohara T, Ono M. DPPH (1,1-diphenyl-2-picrylhydrazyl) radical scavenging activity of flavonoids obtained from some medicinal plants. Biol Pharm Bull. 2001;24:1202–5.PubMed
139.
Zurück zum Zitat Park YC, Rimbach G, Saliou C, Valacchi G, Packer L. Activity of monomeric, dimeric, and trimeric flavonoids on NO production, TNF-alpha secretion, and NF-kappaB-dependent gene expression in RAW 264.7 macrophages. FEBS Lett. 2000;465:93–7.PubMed Park YC, Rimbach G, Saliou C, Valacchi G, Packer L. Activity of monomeric, dimeric, and trimeric flavonoids on NO production, TNF-alpha secretion, and NF-kappaB-dependent gene expression in RAW 264.7 macrophages. FEBS Lett. 2000;465:93–7.PubMed
140.
Zurück zum Zitat Mackenzie GG, Carrasquedo F, Delfino JM, Keen CL, Fraga CG, Oteiza PI. Epicatechin, catechin, and dimeric procyanidins inhibit PMA-induced NF-kappaB activation at multiple steps in Jurkat T cells. FASEB J. 2004;18:167–9.PubMed Mackenzie GG, Carrasquedo F, Delfino JM, Keen CL, Fraga CG, Oteiza PI. Epicatechin, catechin, and dimeric procyanidins inhibit PMA-induced NF-kappaB activation at multiple steps in Jurkat T cells. FASEB J. 2004;18:167–9.PubMed
141.
Zurück zum Zitat Nicholson SK, Tucker GA, Brameld JM. Physiological concentrations of dietary polyphenols regulate vascular endothelial cell expression of genes important in cardiovascular health. Br J Nutr. 2010;103:1398–403.PubMed Nicholson SK, Tucker GA, Brameld JM. Physiological concentrations of dietary polyphenols regulate vascular endothelial cell expression of genes important in cardiovascular health. Br J Nutr. 2010;103:1398–403.PubMed
142.
Zurück zum Zitat Auclair S, Chironi G, Milenkovic D, et al. The regular consumption of a polyphenol-rich apple does not influence endothelial function: a randomized double-blind trial in hypercholesterolemic adults. Eur J Clin Nutr. 2010;64:1158–65.PubMed Auclair S, Chironi G, Milenkovic D, et al. The regular consumption of a polyphenol-rich apple does not influence endothelial function: a randomized double-blind trial in hypercholesterolemic adults. Eur J Clin Nutr. 2010;64:1158–65.PubMed
143.
Zurück zum Zitat Gollucke AP. Recent applications of grape polyphenols in foods, beverages and supplements. Recent Pat Food Nutr Agric. 2010;2:105–9.PubMed Gollucke AP. Recent applications of grape polyphenols in foods, beverages and supplements. Recent Pat Food Nutr Agric. 2010;2:105–9.PubMed
144.
Zurück zum Zitat Hooper L, Kroon PA, Rimm EB, et al. Flavonoids, flavonoid-rich foods, and cardiovascular risk: a meta-analysis of randomized controlled trials. Am J Clin Nutr. 2008;88:38–50.PubMed Hooper L, Kroon PA, Rimm EB, et al. Flavonoids, flavonoid-rich foods, and cardiovascular risk: a meta-analysis of randomized controlled trials. Am J Clin Nutr. 2008;88:38–50.PubMed
145.
Zurück zum Zitat Andriantsitohaina R, Auger C, Chataigneau T, et al. Molecular mechanisms of the cardiovascular protective effects of polyphenols. Br J Nutr. 2012;108:1532–49.PubMed Andriantsitohaina R, Auger C, Chataigneau T, et al. Molecular mechanisms of the cardiovascular protective effects of polyphenols. Br J Nutr. 2012;108:1532–49.PubMed
146.
Zurück zum Zitat Bornhoeft J, Castaneda D, Nemoseck T, Wang P, Henning SM, Hong MY. The protective effects of green tea polyphenols: lipid profile, inflammation, and antioxidant capacity in rats fed an atherogenic diet and dextran sodium sulfate. J Med Food. 2012;15:726–32.PubMed Bornhoeft J, Castaneda D, Nemoseck T, Wang P, Henning SM, Hong MY. The protective effects of green tea polyphenols: lipid profile, inflammation, and antioxidant capacity in rats fed an atherogenic diet and dextran sodium sulfate. J Med Food. 2012;15:726–32.PubMed
147.
Zurück zum Zitat Ras RT, Zock PL, Draijer R. Tea consumption enhances endothelial-dependent vasodilation; a meta-analysis. PLoS One. 2011;6:e16974.PubMedCentralPubMed Ras RT, Zock PL, Draijer R. Tea consumption enhances endothelial-dependent vasodilation; a meta-analysis. PLoS One. 2011;6:e16974.PubMedCentralPubMed
148.
Zurück zum Zitat Fitzpatrick DF, Hirschfield SL, Ricci T, Jantzen P, Coffey RG. Endothelium-dependent vasorelaxation caused by various plant extracts. J Cardiovasc Pharmacol. 1995;26:90–5.PubMed Fitzpatrick DF, Hirschfield SL, Ricci T, Jantzen P, Coffey RG. Endothelium-dependent vasorelaxation caused by various plant extracts. J Cardiovasc Pharmacol. 1995;26:90–5.PubMed
149.
Zurück zum Zitat Schewe T, Steffen Y, Sies H. How do dietary flavanols improve vascular function? A position paper. Arch Biochem Biophys. 2008;476:102–6.PubMed Schewe T, Steffen Y, Sies H. How do dietary flavanols improve vascular function? A position paper. Arch Biochem Biophys. 2008;476:102–6.PubMed
150.
Zurück zum Zitat Visioli F, Galli C. Biological properties of olive oil phytochemicals. Crit Rev Food Sci Nutr. 2002;42:209–21.PubMed Visioli F, Galli C. Biological properties of olive oil phytochemicals. Crit Rev Food Sci Nutr. 2002;42:209–21.PubMed
151.
Zurück zum Zitat Gimeno E, Fito M, Lamuela-Raventos RM, et al. Effect of ingestion of virgin olive oil on human low-density lipoprotein composition. Eur J Clin Nutr. 2002;56:114–20.PubMed Gimeno E, Fito M, Lamuela-Raventos RM, et al. Effect of ingestion of virgin olive oil on human low-density lipoprotein composition. Eur J Clin Nutr. 2002;56:114–20.PubMed
152.
Zurück zum Zitat Tousoulis D, Papageorgiou N, Antoniades C, et al. Acute effects of different types of oil consumption on endothelial function, oxidative stress status and vascular inflammation in healthy volunteers. Br J Nut. 2010;103:43–9. Tousoulis D, Papageorgiou N, Antoniades C, et al. Acute effects of different types of oil consumption on endothelial function, oxidative stress status and vascular inflammation in healthy volunteers. Br J Nut. 2010;103:43–9.
153.
Zurück zum Zitat Papageorgiou N, Tousoulis D, Psaltopoulou T, et al. Divergent anti-inflammatory effects of different oil acute consumption on healthy individuals. Eur J Clin Nutr. 2011;65:514–9.PubMed Papageorgiou N, Tousoulis D, Psaltopoulou T, et al. Divergent anti-inflammatory effects of different oil acute consumption on healthy individuals. Eur J Clin Nutr. 2011;65:514–9.PubMed
154.
Zurück zum Zitat Pitsavos C, Panagiotakos DB, Tzima N, et al. Adherence to the Mediterranean diet is associated with total antioxidant capacity in healthy adults: the ATTICA study. Am J Clin Nutr. 2005;82:694–9.PubMed Pitsavos C, Panagiotakos DB, Tzima N, et al. Adherence to the Mediterranean diet is associated with total antioxidant capacity in healthy adults: the ATTICA study. Am J Clin Nutr. 2005;82:694–9.PubMed
155.
Zurück zum Zitat Salami M, Galli C, De Angelis L, Visioli F. Formation of F2-isoprostanes in oxidized low density lipoprotein: inhibitory effect of hydroxytyrosol. Pharmacol Res: Off J Ital Pharmacol Soc. 1995;31:275–9. Salami M, Galli C, De Angelis L, Visioli F. Formation of F2-isoprostanes in oxidized low density lipoprotein: inhibitory effect of hydroxytyrosol. Pharmacol Res: Off J Ital Pharmacol Soc. 1995;31:275–9.
156.
Zurück zum Zitat Khurana S, Venkataraman K, Hollingsworth A, Piche M, Tai TC. Polyphenols: benefits to the cardiovascular system in health and in aging. Nutrients. 2013;5:3779–827.PubMedCentralPubMed Khurana S, Venkataraman K, Hollingsworth A, Piche M, Tai TC. Polyphenols: benefits to the cardiovascular system in health and in aging. Nutrients. 2013;5:3779–827.PubMedCentralPubMed
157.
Zurück zum Zitat Masella R, Vari R, D'Archivio M, et al. Extra virgin olive oil biophenols inhibit cell-mediated oxidation of LDL by increasing the mRNA transcription of glutathione-related enzymes. J Nutr. 2004;134:785–91.PubMed Masella R, Vari R, D'Archivio M, et al. Extra virgin olive oil biophenols inhibit cell-mediated oxidation of LDL by increasing the mRNA transcription of glutathione-related enzymes. J Nutr. 2004;134:785–91.PubMed
158.
Zurück zum Zitat Hollman PC, Cassidy A, Comte B, et al. The biological relevance of direct antioxidant effects of polyphenols for cardiovascular health in humans is not established. J Nutr. 2011;141:989S–1009S.PubMed Hollman PC, Cassidy A, Comte B, et al. The biological relevance of direct antioxidant effects of polyphenols for cardiovascular health in humans is not established. J Nutr. 2011;141:989S–1009S.PubMed
159.
Zurück zum Zitat Kalen A, Appelkvist EL, Dallner G. Age-related changes in the lipid compositions of rat and human tissues. Lipids. 1989;24:579–84.PubMed Kalen A, Appelkvist EL, Dallner G. Age-related changes in the lipid compositions of rat and human tissues. Lipids. 1989;24:579–84.PubMed
160.
Zurück zum Zitat Ochiai A, Itagaki S, Kurokawa T, Kobayashi M, Hirano T, Iseki K. Improvement in intestinal coenzyme q10 absorption by food intake. Yakugaku zasshi: J Pharm Soc Japan. 2007;127:1251–4. Ochiai A, Itagaki S, Kurokawa T, Kobayashi M, Hirano T, Iseki K. Improvement in intestinal coenzyme q10 absorption by food intake. Yakugaku zasshi: J Pharm Soc Japan. 2007;127:1251–4.
161.
Zurück zum Zitat Lee BJ, Tseng YF, Yen CH, Lin PT. Effects of coenzyme Q10 supplementation (300 mg/day) on antioxidation and anti-inflammation in coronary artery disease patients during statins therapy: a randomized, placebo-controlled trial. Nutr J. 2013;12:142.PubMedCentralPubMed Lee BJ, Tseng YF, Yen CH, Lin PT. Effects of coenzyme Q10 supplementation (300 mg/day) on antioxidation and anti-inflammation in coronary artery disease patients during statins therapy: a randomized, placebo-controlled trial. Nutr J. 2013;12:142.PubMedCentralPubMed
162.
Zurück zum Zitat Gao L, Mao Q, Cao J, Wang Y, Zhou X, Fan L. Effects of coenzyme Q10 on vascular endothelial function in humans: a meta-analysis of randomized controlled trials. Atherosclerosis. 2012;221:311–6.PubMed Gao L, Mao Q, Cao J, Wang Y, Zhou X, Fan L. Effects of coenzyme Q10 on vascular endothelial function in humans: a meta-analysis of randomized controlled trials. Atherosclerosis. 2012;221:311–6.PubMed
163.
Zurück zum Zitat Tiyerili V, Zimmer S, Jung S, et al. CB1 receptor inhibition leads to decreased vascular AT1 receptor expression, inhibition of oxidative stress and improved endothelial function. Basic Res Cardiol. 2010;105:465–77.PubMed Tiyerili V, Zimmer S, Jung S, et al. CB1 receptor inhibition leads to decreased vascular AT1 receptor expression, inhibition of oxidative stress and improved endothelial function. Basic Res Cardiol. 2010;105:465–77.PubMed
164.
Zurück zum Zitat Van Gaal LF, Scheen AJ, Rissanen AM, Rossner S, Hanotin C, Ziegler O. Long-term effect of CB1 blockade with rimonabant on cardiometabolic risk factors: two year results from the RIO-Europe study. Eur Heart J. 2008;29:1761–71.PubMed Van Gaal LF, Scheen AJ, Rissanen AM, Rossner S, Hanotin C, Ziegler O. Long-term effect of CB1 blockade with rimonabant on cardiometabolic risk factors: two year results from the RIO-Europe study. Eur Heart J. 2008;29:1761–71.PubMed
165.
Zurück zum Zitat O'Donnell BV, Tew DG, Jones OT, England PJ. Studies on the inhibitory mechanism of iodonium compounds with special reference to neutrophil NADPH oxidase. Biochem J. 1993;290(1):41–9.PubMedCentralPubMed O'Donnell BV, Tew DG, Jones OT, England PJ. Studies on the inhibitory mechanism of iodonium compounds with special reference to neutrophil NADPH oxidase. Biochem J. 1993;290(1):41–9.PubMedCentralPubMed
166.
Zurück zum Zitat Kinkade K, Streeter J, Miller FJ. Inhibition of NADPH oxidase by apocynin attenuates progression of atherosclerosis. Int J Mol Sci. 2013;14:17017–28.PubMedCentralPubMed Kinkade K, Streeter J, Miller FJ. Inhibition of NADPH oxidase by apocynin attenuates progression of atherosclerosis. Int J Mol Sci. 2013;14:17017–28.PubMedCentralPubMed
167.
Zurück zum Zitat Liu Y, Davidson BP, Yue Q, et al. Molecular imaging of inflammation and platelet adhesion in advanced atherosclerosis effects of antioxidant therapy with NADPH oxidase inhibition. Circ Cardiovasc Imaging. 2013;6:74–82.PubMedCentralPubMed Liu Y, Davidson BP, Yue Q, et al. Molecular imaging of inflammation and platelet adhesion in advanced atherosclerosis effects of antioxidant therapy with NADPH oxidase inhibition. Circ Cardiovasc Imaging. 2013;6:74–82.PubMedCentralPubMed
168.
Zurück zum Zitat Khanicheh E, Qi Y, Xie A, et al. Molecular imaging reveals rapid reduction of endothelial activation in early atherosclerosis with apocynin independent of antioxidative properties. Arterioscler Thromb Vasc Biol. 2013;33:2187–92.PubMedCentralPubMed Khanicheh E, Qi Y, Xie A, et al. Molecular imaging reveals rapid reduction of endothelial activation in early atherosclerosis with apocynin independent of antioxidative properties. Arterioscler Thromb Vasc Biol. 2013;33:2187–92.PubMedCentralPubMed
169.
Zurück zum Zitat Schramm A, Matusik P, Osmenda G, Guzik TJ. Targeting NADPH oxidases in vascular pharmacology. Vasc Pharmacol. 2012;56:216–31. Schramm A, Matusik P, Osmenda G, Guzik TJ. Targeting NADPH oxidases in vascular pharmacology. Vasc Pharmacol. 2012;56:216–31.
170.
Zurück zum Zitat Rey FE, Cifuentes ME, Kiarash A, Quinn MT, Pagano PJ. Novel competitive inhibitor of NAD(P)H oxidase assembly attenuates vascular O(2)(−) and systolic blood pressure in mice. Circ Res. 2001;89:408–14.PubMed Rey FE, Cifuentes ME, Kiarash A, Quinn MT, Pagano PJ. Novel competitive inhibitor of NAD(P)H oxidase assembly attenuates vascular O(2)(−) and systolic blood pressure in mice. Circ Res. 2001;89:408–14.PubMed
Metadaten
Titel
Oxidative Stress and Early Atherosclerosis: Novel Antioxidant Treatment
verfasst von
Dimitris Tousoulis
Theodora Psaltopoulou
Emmanuel Androulakis
Nikolaos Papageorgiou
Spyridon Papaioannou
Evangelos Oikonomou
Andreas Synetos
Christodoulos Stefanadis
Publikationsdatum
01.02.2015
Verlag
Springer US
Erschienen in
Cardiovascular Drugs and Therapy / Ausgabe 1/2015
Print ISSN: 0920-3206
Elektronische ISSN: 1573-7241
DOI
https://doi.org/10.1007/s10557-014-6562-5

Weitere Artikel der Ausgabe 1/2015

Cardiovascular Drugs and Therapy 1/2015 Zur Ausgabe

Ist Fasten vor Koronarinterventionen wirklich nötig?

Wenn Eingriffe wie eine Koronarangiografie oder eine Koronarangioplastie anstehen, wird häufig empfohlen, in den Stunden zuvor nüchtern zu bleiben. Ein französisches Forscherteam hat diese Maßnahme hinterfragt.

PET kann infarktgefährdete Koronararterien entdecken

04.06.2024 Koronare Herzerkrankung Nachrichten

Der Nachweis aktiver Plaques mittels 18F-Natriumfluorid-PET hilft nicht nur, infarktgefährdete Patienten, sondern auch infarktgefährdete Koronararterien zu erkennen. Von einer gezielten Behandlung vulnerabler Plaques ist man trotzdem weit entfernt.

GLP-1-Agonist Semaglutid wirkt kardio- und nephroprotektiv

03.06.2024 Semaglutid Nachrichten

Der GLP-1-Agonist Semaglutid hat in der FLOW-Studie bewiesen, dass sich damit die Progression chronischer Nierenerkrankungen bei Patienten mit Typ-2-Diabetes bremsen lässt. Auch in kardiovaskulärer Hinsicht war die Therapie erfolgreich.

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

29.05.2024 Herzinfarkt Nachrichten

Bei Menschen mit Typ-2-Diabetes sind die Chancen, einen Myokardinfarkt zu überleben, in den letzten 15 Jahren deutlich gestiegen – nicht jedoch bei Betroffenen mit Typ 1.

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.